Authors
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Advanced Penile Cancer Presenting With Renal Failure“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
Latest:
Highlighting Breast Cancer Advances at IBC EastLeading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Latest:
PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment LandscapePanelists discuss ongoing clinical trials and how the treatment landscape for HR positive (HR+)/ HER2 negative (HER2-) breast cancer is evolving with novel targeted therapies and combination strategies, with Dr Isaacs highlighting the most exciting aspects of these trials and their potential impact on the future of precision medicine in this patient population.
Latest:
Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic MalignanciesCancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentZenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Latest:
Phyllis Morgan on Health Disparities in Patients At Risk for Developing Colorectal CancerPhyllis Morgan, PhD, sat down with CancerNetwork® to discuss health disparities during Colorectal Cancer Awareness Month.
Latest:
Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLLTreatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
Latest:
Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community CenterPanelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
Latest:
Outlining Emergent Toxicities in Standard Ovarian Cancer TreatmentOncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Latest:
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLCExperts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Latest:
Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional FractionationABSTRACT Symptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited survival and poor patient performance in that setting. In the era of targeted and personalized therapies, many patients are living longer and more functionally and are able to manage their disease on the model of chronic illness. Given these developments, an attractive option is the use of stereotactic body radiation therapy (SBRT) to deliver high biologically effective doses of radiation conformally to maximize the palliative gains of treatment. However, randomized data to guide practice are scarce. We review the extant literature and present an algorithmic approach to selecting patients with metastatic disease for palliative spinal SBRT favoring the results of available randomized studies and remaining within the safety constraints supported by evidence from randomized trials.
Latest:
Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic FeaturesA patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.
Latest:
Value of Geriatric Assessment in Patients With Genitourinary CarcinomaThis work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
Latest:
Expert Commentary on the Product Profile of Enfortumab Vedotin Plus PembrolizumabKirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, gives his perspective on the approval of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.
Latest:
Future Directions and Collaborations in Multiple MyelomaPanelists discuss how future directions in multiple myeloma include exciting developments like bispecific T-cell engagers (BiTEs) targeting B-cell maturation antigen (BCMA) and GPRC5D, dual-target chimeric antigen receptor (CAR) T therapies, and revolutionary in vivo CAR T approaches, while emphasizing the importance of nurse education and advocacy, compassionate patient-centered care, and a collaborative community approach where academic centers support community oncologists through accessible communication and shared care, ultimately working toward the goal of curing more patients, as evidenced by one-third of ciltacabtagene autoleucel (cilta-cel) recipients remaining in remission 5 years later without additional therapy.
Latest:
Unmet Needs and Future Perspectives in the Treatment of CLLThe panel shares some final thoughts on unmet needs and the future of CLL treatment.
Latest:
Examining Neoadjuvant Chemoimmunotherapy Benefit in Stage III Lung CancersPatients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
